BioCardia, Inc. is a clinical stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. Its lead therapeutic candidate is the CardiAMP cell therapy system and its second therapeutic candidate is the CardiALLO cell therapy system. BioCardia is headquartered in San Carlos, California.
Quote | BioCardia Inc. (OTCMKTS:BCDA)
Last: | $ |
---|---|
Change Percent: | 3.10% |
Open: | $4.73 |
Close: | $4.66 |
High: | $4.73 |
Low: | $4.6348 |
Volume: | 2,064 |
Last Trade Date Time: | 02/12/2020 04:27:18 pm |
News | BioCardia Inc. (OTCMKTS:BCDA)
2024-03-27 20:00:12 ET BioCardia, Inc. (BCDA) Q4 2023 Results Conference Call March 27, 2024 04:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and Chief Executive Officer David McClung - Chief Financial Officer Pres...
2024-03-27 16:17:20 ET More on BioCardia BioCardia spikes after Medicare coverage for cell therapy trial Seeking Alpha’s Quant Rating on BioCardia Historical earnings data for BioCardia Financial information for BioCardia Read the full articl...
Message Board Posts | BioCardia Inc. (OTCMKTS:BCDA)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $BCDA News Article - BioCardia Letter to Shareholders | whytestocks | investorshangout | 12/22/2022 4:15:44 PM |
whytestocks: $BCDA News Article - BioCardia Reports Third Quarter 2022 Business Highlights and Finan | whytestocks | investorshangout | 11/09/2022 9:15:53 PM |
whytestocks: $BCDA News Article - BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Tr | whytestocks | investorshangout | 10/03/2022 4:50:59 PM |
whytestocks: $BCDA News Article - BioCardia to Participate in Cantor Fitzgerald's Cell and Genetic M | whytestocks | investorshangout | 09/08/2022 5:30:48 PM |
whytestocks: $BCDA News Article - BioCardia Announces Positive DSMB Review and Recommendation to Con | whytestocks | investorshangout | 08/31/2022 2:20:49 PM |
News, Short Squeeze, Breakout and More Instantly...
SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2023 and filed its ann...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
SUNNYVALE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics...